Teva Pharmaceutical Industries (TEVA) investor relations material

Study design and context

• Ongoing phase IIa trial of atabinib plus modified gemcitabine and nab-paclitaxel in first-line pancreatic cancer patients, with a data cutoff of August 26, 2025.

• 34 patients enrolled, median age 69, with a significant proportion having liver metastases.

• Study population is older than those in pivotal studies for standard of care, with similar distribution of metastases.

• No genetic testing required for enrollment, allowing for a broad patient population.

• Study funded through 2029 following a $175M underwritten offering and $25M private placement, including strategic investment from Sanofi.

Efficacy results

• Six-month overall survival (OS) was 94%, and nine-month OS was 86%, nearly double the benchmark for standard of care.

• Median overall survival not yet reached due to a flat survival curve.

• Progression-free survival (PFS) at six months was 70%, and at nine months was 53%, with a median PFS of 9.6 months.

• Strong separation in OS and PFS compared to all three standard of care regimens, including gemcitabine+nab-paclitaxel, FOLFIRINOX, and NALIRIFOX.

• Subgroup analysis showed identical PFS for patients with liver metastases as the overall population.

Robustness and supporting endpoints

• Results supported by 95% confidence intervals, with even the lower bound showing significant separation from standard of care.

• Surrogate endpoints (overall response rate 39%, disease control rate 81%) also favor atabinib over benchmarks.

• Waterfall and spider plots show most patients have shrinking lesions, with slow, durable responses.

• Lower rate of censoring than typical for oncology studies, further supporting data robustness.

• Efficacy observed in both older and younger, higher fitness patients, and in those with liver metastases.